Announced
Completed
Financials
Sources
Tags
Single Bidder
Friendly
Minority
health care
Private Equity
Acquisition
Private
artificial intelligence
Completed
Venture Capital
Medical Services
Domestic
United States
biotechnology
Synopsis
Koch Disruptive Technologies, a venture capital firm that invests in technologies to improve businesses and create new opportunities, led a $73 Series B round in Deepcell, a life science company pioneering AI-powered single cell classification and isolation for basic and translational research, with participation from Bridger Healthcare, Horizons Ventures, Casdin Capital, Andreessen Horowitz, Bow Capital, Jeff Dean, and Matt Mcllwain. “The new funding will help us to accelerate our growth, develop our platform, and take a major step toward full commercialization. The support we are receiving highlights the potential of Deepcell’s AI-powered single cell morphology analysis, and enables us to expand the team, transition to late-stage development and accelerate towards introducing our platform to a present and growing list of potential customers,” Maddison Masaeli, Deepcell CEO and Co-founder.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.